Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Jun 28, 2020; 8(3): 220-232
Published online Jun 28, 2020. doi: 10.13105/wjma.v8.i3.220
Published online Jun 28, 2020. doi: 10.13105/wjma.v8.i3.220
Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease
Kamran Qureshi, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States
Alan Bonder, Division of Gastroenterology/Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
Author contributions: Qureshi K and Bonder A conceived of the review, assisted in writing and revising the various drafts of the paper, and agreed on the final version.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Alan Bonder, MD, Attending Doctor, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, 110 Francis St. Suite 8E, Boston, MA 02215, United States. abonder@bidmc.harvard.edu
Received: March 2, 2020
Peer-review started: March 2, 2020
First decision: April 24, 2020
Revised: May 20, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: June 28, 2020
Peer-review started: March 2, 2020
First decision: April 24, 2020
Revised: May 20, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: June 28, 2020
Core Tip
Core tip: Thrombocytopenia in patients with chronic liver disease complicates perioperative planning. Platelet transfusions are typically used as periprocedural treatment in these patients, but their use is complicated due to risk factors such as the development of infections and refractoriness. This has led to the development of thrombopoietin-receptor agonists, such as avatrombopag and lusutrombopag, that can increase platelet counts in patients with compromised thrombopoietin production and chronic liver disease. These thrombopoietin-receptor agonists can provide physicians with a safe and effective alternative to platelet transfusions and their use in clinical practice is the focus of this review.